Immune requirements for protective Th17 recall responses to Mycobacterium tuberculosis challenge.
about
Targeting dendritic cells to accelerate T-cell activation overcomes a bottleneck in tuberculosis vaccine efficacyLeprosy Reactions Show Increased Th17 Cell Activity and Reduced FOXP3+ Tregs with Concomitant Decrease in TGF-β and Increase in IL-6Avidity of human T cell receptor engineered CD4(+) T cells drives T-helper differentiation fateNovel adjuvant formulations for delivery of anti-tuberculosis vaccine candidatesStimulation through CD40 and TLR-4 Is an Effective Host Directed Therapy against Mycobacterium tuberculosis.Neonatal Fc Receptor Regulation of Lung Immunoglobulin and CD103+ Dendritic Cells Confers Transient Susceptibility to Tuberculosis.A novel multivalent tuberculosis vaccine confers protection in a mouse model of tuberculosis.The IL-17A rs2275913 single nucleotide polymorphism is associated with protection to tuberculosis but related to higher disease severity in Argentina.Engineering mycobacteria for the production of self-assembling biopolyesters displaying mycobacterial antigens for use as tuberculosis vaccine.Subunit vaccine H56/CAF01 induces a population of circulating CD4 T cells that traffic into the Mycobacterium tuberculosis-infected lungInteractions between Type 1 Interferons and the Th17 Response in Tuberculosis: Lessons Learned from Autoimmune Diseases.Cytokines and Chemokines in Mycobacterium tuberculosis Infection.Yin and yang of interleukin-17 in host immunity to infection.The Role of Neutrophils in the Induction of Specific Th1 and Th17 during Vaccination against Tuberculosis.Protective vaccine efficacy of the complete form of PPE39 protein from Mycobacterium tuberculosis Beijing/K strain in mice.IL-21 Receptor Signaling Is Essential for Optimal CD4+ T Cell Function and Control of Mycobacterium tuberculosis Infection in Mice.A novel nanoemulsion vaccine induces mucosal Interleukin-17 responses and confers protection upon Mycobacterium tuberculosis challenge in mice.Rationalized design of a mucosal vaccine protects against Mycobacterium tuberculosis challenge in mice.CHO expressed recombinant human lactoferrin as an adjuvant for BCG.Circulating Mycobacterium tuberculosis DosR latency antigen-specific, polyfunctional, regulatory IL10+ Th17 CD4 T-cells differentiate latent from active tuberculosisEffects of Th17 cells and IL-17 in the progression of cervical carcinogenesis with high-risk human papillomavirus infection.
P2860
Q28354371-293D5714-1A9B-45D5-A09E-D87EC09115A4Q35976768-88195DD8-844F-4924-83C1-96DEFF26102AQ36684961-3729FEC0-8D6C-4077-A7C7-015C05268CA6Q36909492-8AA0FA8A-E4FD-43E4-A228-0DEA71E23F0CQ37284865-BF1D17E1-43F4-45B6-B882-47AAB00E4046Q37287212-67100A2A-C1B2-4982-8B0D-6A9579FD8318Q37375963-146C58D7-05A0-428E-AEED-B2AA815D41D2Q37591092-AC5178D6-E762-4156-971D-7514EDBA82A2Q37644063-54159546-C44F-44B9-8303-CDBDC5CF91E2Q37666257-EC6894FB-4499-42D4-B5C7-87740FA4A720Q37737549-0152402C-DA35-4BA8-BC86-FF0CD8382AF2Q38986062-97CBD06E-59BD-4D49-9C96-C7DDF5A609B8Q39438071-6DEE7228-028F-499D-BDCD-F8EB12B54978Q39533192-F73E8897-5EBE-4BA9-A880-314068F4C3CCQ40064027-B3D838A6-90C6-4D67-A96B-850C30843354Q40074071-63AA6AE3-AAB0-441E-8553-7A3DD61C800DQ40107672-43D026D2-04F6-4284-A85A-28066B57ECFBQ40309267-B8916B98-2F0F-4419-88EC-6992DFE93486Q41028714-325DFF86-F11C-4E42-8C05-4C0B859F5B61Q41697005-C6A4F8FE-4116-4EA8-A8B1-76680A519947Q48349463-008D211D-1F40-42CA-AF4F-0025324383EF
P2860
Immune requirements for protective Th17 recall responses to Mycobacterium tuberculosis challenge.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Immune requirements for protec ...... terium tuberculosis challenge.
@en
type
label
Immune requirements for protec ...... terium tuberculosis challenge.
@en
prefLabel
Immune requirements for protec ...... terium tuberculosis challenge.
@en
P2093
P2860
P356
P1433
P1476
Immune requirements for protec ...... cterium tuberculosis challenge
@en
P2093
P2860
P2888
P304
P356
10.1038/MI.2014.136
P577
2015-01-28T00:00:00Z